Radioisotopes reborn: radium‐223 and its role in the management of prostate cancer
This report is based on a seminar held during the 11th Annual Meeting of the British Uro‐oncology Group (BUG) in London, 12–13 September 2014. The seminar discussed the development of radium‐223 and its role in the management of prostate cancer, including an overview of the ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) trial and practical issues around the integration of radium‐223 into clinical practice.
Source: Trends in Urology, Gynaecology and Sexual Health - Category: OBGYN Authors: Chris Parker, Joe O'Sullivan, Catherine Heath Tags: Reports Source Type: research